Concentration of sRAGE, esRAGE and HMGB1 in serum of patients.

The basic characteristics of patients with TETs, TH and healthy volunteers are detailed. Characterization and categorization of patients with TETs according to type of TET, tumor invasiveness and presence of MG: the corresponding sRAGE, esRAGE and HMGB1 concentration in serum of patients are reported is mean (median) ± standard deviation (standard error mean).
aPost hoc analysis: please see the corresponding figures.
bindependent-samples t-test
cone-way ANOVA
dPearson's χ2 test for independence
f:m ratio female:male ratio, RAGE receptor for advanced glycation endproducts, sRAGE soluble RAGE, esRAGE endogenous secretory RAGE, HMGB1 high mobility group box1, TETs thymic epithelial tumors, MG Myasthenia gravis, SEM standard error mean, n number of patients, TH thymic hyperplasia, TC thymic carcinoma

本数据集详细阐述了胸腺上皮肿瘤（thymic epithelial tumors, TETs）患者、胸腺增生（thymic hyperplasia, TH）患者以及健康志愿者的基线特征。研究人员根据胸腺上皮肿瘤分型、肿瘤侵袭性以及是否合并重症肌无力（Myasthenia gravis, MG）对胸腺上皮肿瘤患者进行特征描述与分类，并报告了患者血清中可溶性RAGE（soluble RAGE, sRAGE）、内泌型RAGE（endogenous secretory RAGE, esRAGE）与高迁移率族蛋白B1（high mobility group box1, HMGB1）的浓度，结果以均值（中位数）±标准差（标准误，standard error mean, SEM）的形式呈现。
a 事后检验分析：详见对应图表。
b 独立样本t检验
c 单因素方差分析（one-way ANOVA）
d 皮尔逊卡方独立性检验（Pearson's χ2 test for independence）
本数据集涉及的缩写说明如下：f:m指男女比例（female:male ratio）；RAGE为晚期糖基化终产物受体（receptor for advanced glycation endproducts）；sRAGE为可溶性RAGE（soluble RAGE）；esRAGE为内泌型RAGE（endogenous secretory RAGE）；HMGB1为高迁移率族蛋白B1（high mobility group box1）；TETs为胸腺上皮肿瘤（thymic epithelial tumors）；MG为重症肌无力（Myasthenia gravis）；SEM为标准误（standard error mean）；n为患者例数（number of patients）；TH为胸腺增生（thymic hyperplasia）；TC为胸腺癌（thymic carcinoma）。